Skip to main content
Fig. 4 | Allergy, Asthma & Clinical Immunology

Fig. 4

From: Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials

Fig. 4

Participants Asymptomatic at Peanut Protein Doses  ≤ 100 mg in the Exit DBPCFC. Freedom from symptoms up to 100 mg of peanut protein in randomized, controlled trials only. Freedom from symptoms indicated participants were asymptomatic to peanut exposure during the entire DBPCFC. aRR (PTAH vs placebo) for any symptoms in the intention-to-treat population. CI confidence interval, DBPCFC double-blind, placebo-controlled food challenge, PTAH peanut (Arachis hypogaea) allergen powder-dnfp, RR relative risk

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us